BioNTech posts Q3 profit, raises FY revenue outlook as oncology pipeline advances
+2 new sources since this summary was written
BioNTech SE reported third‑quarter 2026 revenue of €1.289 billion, a 15% year‑over‑year decline driven by lower COVID‑19 vaccine sales, but returned to profitability with a net profit of €184.5 million. The company raised its full‑year 2026 revenue guidance midpoint to a range of €1.7‑€1.9 billion and highlighted progress in its oncology pipeline, including Phase 3 trials for pumitamig combinations and strong survival data for gotistobart. Cash and investments stood at €16.2 billion at quarter end.
Why it matters
The raised revenue guidance signals management confidence in partnership milestones and oncology growth, which may support the stock despite the revenue decline (the company said the outlook reflects stronger Q3 performance). The return to profit and a €16.2 billion cash position give the firm runway to fund its R&D programs and potential acquisitions.
Key facts
- 1Q3 2026 revenue was €1,289.2 million, down from €1,518.9 million in Q3 2025. finanznachrichten.de
- 2Net profit for Q3 2026 was €184.5 million, compared with a loss of €28.7 million a year earlier. finanznachrichten.de
- 3Cash, cash equivalents and security investments totaled €16.2 billion as of September 30 2026. finanznachrichten.de
- 4Full‑year 2026 revenue guidance was raised to €1.7 billion‑€1.9 billion, up from the prior €1.6 billion‑€1.9 billion range. finanznachrichten.de
- 5IFRS research and development expenses for Q3 2026 were €748.1 million. finanznachrichten.de
- 6Adjusted R&D expenses for Q3 2026 were €578.5 million. finanznachrichten.de
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.